Previous 10 | Next 10 |
2024-05-07 16:52:18 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earning...
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference cal...
2024-05-07 08:02:01 ET More on Ligand Pharmaceuticals Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Read the f...
Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activities Ligand entitled to royalties and milestone payments on six Agenus-partnered programs as well as royalties on future global net sales gener...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-02 15:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-29 22:01:18 ET Summary Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry. These companies buy up royalty rights to pharmaceutical products, providing upfront cash to biotech companies. This allows biotech companies...
2024-04-25 10:05:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0% since inception, compa...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results a...
2024-04-18 13:26:38 ET Summary Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz, but Jazz is defend...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...